Navigation Links
ExoCoBio Published a Research Paper on 'The World's First Exosome-Based Treatment for Atopic Dermatitis'
Date:8/26/2018

ExoCoBio Inc., based in South Korea, published a scientific paper on that stem cell-derived exosomes dramatically relieves atopic dermatitis and inhibits a variety of inflammatory targets in the journal of Stem Cell Research and Therapy.

According to the paper, the symptoms of mice having severe atopic dermatitis were significantly improved after administration of stem cell-derived exosomes intravenously or subcutaneously, so that the level of serum immunoglobulin E (IgE), the number of eosinophils in blood, and the number of mast cells in the skin lesion were decreased. It has also been found that the number of inflammatory dendritic epidermal cells (IDECs), which are not found in normal skin but cause an allergic inflammatory response in atopic dermatitis lesions, also significantly decreased to a normal skin level after administration of stem cell-derived exosomes. In addition, the improvement of the symptoms by stem cell-derived exosomes was comparable to that of a steroid drug, Prednisolone.

While atopic dermatitis is a chronic disease depreciating the quality of life, there is no fundamental treatment to treat it yet. Currently available atopic treatments, such as anti-histamines, steroids and immunosuppressive drugs, have various side effects such as impaired immune systems, liver & kidney damage during long-term administration, etc. Inhibitory antibodies against various inflammatory cytokines such as IL-4, IL-31, TNF-alpha and IL-23 are under development or on the market to relieve atopic dermatitis symptoms. However, these treatments just relieve atopic dermatitis by blocking the function of one or two specific proteins.

Meanwhile, the new drug candidate based on stem cell-derived exosomes, which is being developed by ExoCoBio, can modulate the activity of various immune cells causing dermatitis, with a mechanism that fundamentally inhibits the production of inflammatory cytokines. Moreover, it is highly anticipated that stem cell-derived exosomes will become the first-in-class therapeutic for atopic dermatitis that has powerful anti-inflammatory activities and with little side effects for long-term repeated administration.

"It is so proud to be the world’s first to publish the research results that stem cell-derived exosomes have very important therapeutic efficacy for atopic dermatitis. ExoCoBio will keep focusing on developing innovative biopharmaceuticals based on stem cell-derived exosomes," said Byong Cho, the CEO of ExoCoBio.

"Stem cell-derived exosomes are believed as a fundamental treatment for a variety of inflammatory diseases because they have strong anti-inflammatory effects. This study shows that stem cell-derived exosomes are very effective to improve severe atopic dermatitis," said Dr. Joon Lee, dermatologist and medical advisor of ExoCoBio.

Figure 1. Results showing therapeutic effects of stem cell-derived exosomes on atopic dermatitis. After administration of stem cell-derived exosomes in the mice with severe atopic dermatitis through either intravenously or subcutaneously, symptoms of atopic dermatitis were significantly improved in a dose-dependent manner.

https://stemcellres.biomedcentral.com/track/pdf/10.1186/s13287-018-0939-5

Read the full story at https://www.prweb.com/releases/exocobio_published_a_research_paper_on_the_world_s_first_exosome_based_treatment_for_atopic_dermatitis/prweb15711898.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. ExoCoBio Inc. attracts Series A investment of US$11 million
2. Three-Step Rust Removal With a Non-Invasive Rust Remover Published by My Cleaning Products, MCP Offers Sample of the Product
3. Nutra Pharma Patent and Trademarks Published in India
4. BioProcess International March 2013 Issue Published on the App Store Featuring App-only Exclusive Content
5. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
6. How to Kill Fleas Guide Published by My Cleaning Products Along with Launch of Its Pesticide Exempt Flea Control Product
7. New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests
8. Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology
9. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
10. Scientific Proceedings Published, Challenging Conventional Neo-Darwinian Theory
11. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2018)... ... August 30, 2018 , ... Small, wireless and networked describes more ... and getting connected, too. Draper’s latest system is tiny in size, but is poised ... driving factor in the new implant design is the growing awareness that disease often ...
(Date:8/29/2018)... ... August 28, 2018 , ... Inc. Magazine has announced that ... in 1138th place on the 27th annual Inc. 5000, the most prestigious ranking ... most successful companies within the American economy’s most dynamic segment – independent small ...
(Date:8/29/2018)... SANTA BARBARA, Calif. (PRWEB) , ... August 28, 2018 , ... ... process optimization firm for the life sciences and healthcare industries, announces that Manu Vohra ... CA on August 30th. , What: “How to Implement Box for GxP in ...
(Date:8/23/2018)... , ... August 22, 2018 , ... ... for Android on September 1st, making it the first fully-featured app for electronic ... Android devices. Combined, iOS and Android constitute 99 percent of the market share ...
Breaking Biology Technology:
(Date:8/23/2018)... Calif. (PRWEB) , ... August 21, 2018 , ... ... engineer the genomes of diverse cell types and species for the robust functional ... research tool for the development of T-cell based immunotherapies, the study of the ...
(Date:8/23/2018)... ... ... is proud to have hosted a variety of groups this year – both new guests ... Hewlett Packard, Sequenom and more, have all visited the La Jolla-based venue time and time ... reason clientele return is due to Lajollacooks4u’s signature team-building format, a way for teams to ...
(Date:8/21/2018)... ... August 20, 2018 , ... ... for biopharma R&D, today announced that Seattle-based Aptevo Therapeutics , a ... Aptevo will use the Genedata Biologics ® platform to facilitate expansion ...
Breaking Biology News(10 mins):